The relationship between HMOX1 and MAPK14 with the onset and prognosis of sepsis-induced acute lung injury in children

doi:10.11958/20251919

Abstract

Abstract:

Objective To explore the relationship between the ferroptosis-related molecules heme oxygenase-1 (HMOX1) and mitogen-activated protein kinase 14 (MAPK14) with the onset and prognosis of acute lung injury (ALI) in children with sepsis. Methods A total of 102 children with sepsis were selected, including 54 in the ALI group and 48 in the non-ALI group. Clinical data, laboratory tests, organ function scores and serum levels of HMOX1 and MAPK14 were compared between the two groups. The mortality rates of children with different levels of HMOX1 and MAPK14 at 28-day and 90-day were analyzed. Results Compared with the non-ALI group, procalcitonin (PCT), lactate (Lac), pediatric organ dysfunction Logistic-2 score (PELOD-2), pediatric risk of mortality score version 3 (PRISM III) and sequential organ failure assessment (SOFA) scores were increased in the ALI group (P<0.05). Serum levels of HMOX1 and MAPK14 were significantly higher in the ALI group than those in the non-ALI group (P<0.05). HMOX1 and MAPK14 showed good predictive value for the occurrence of ALI in sepsis patients, with AUC values of 0.872 (95%CI: 0.791-0.930) and 0.825 (95%CI:0.737-0.893), and the optimal cutoff values were 3.1 μg/L and 3.8 μg/L, respectively. After grouping by the cutoff values of HMOX1 and MAPK14, there were no significant differences in the 28-day and 90-day mortality rates in children with different levels of HMOX1 and MAPK14 (P>0.05). Conclusion The expression levels of serum HMOX1 and MAPK14 increase in the early stage of sepsis-related ALI, which may serve as biomarkers for the onset of ALI, and they have no significant impact on the prognosis of children.

Key words: sepsis, acute lung injury, ferroptosis, heme oxygenase-1, mitogen-activated protein kinase 14, prognosis, child

CLC Number:

R726.31

Figures/Tables 7

References 21

[1]	CECCONI M, EVANS L, LEVY M, et al. Sepsis and septic shock[J]. Lancet, 2018, 392(10141):75-87. doi:10.1016/S0140-6736(18)30696-2.
[2]	DESPOSITO L, BASCARA C. Review:sepsis guidelines and core measure bundles[J]. Postgrad Med, 2024, 136(7):702-711. doi:10.1080/00325481.2024.2388021.
[3]	ARINA P, HOFMAENNER D A, SINGER M. Definition and epidemiology of sepsis[J]. Semin Respir Crit Care Med, 2024, 45(4):461-468. doi:10.1055/s-0044-1787990.
[4]	CHENG H, WANG X, YAO J, et al. Mitophagy and ferroptosis in sepsis-induced ALI/ARDS:molecular mechanisms,interactions and therapeutic prospects of medicinal plants[J]. J Inflamm Res, 2024, 17:7819-7835.
[5]	HUANG Q, DING Y, FANG C, et al. The emerging role of ferroptosis in sepsis,opportunity or challenge?[J]. Infect Drug Resist, 2023, 16:5551-5562. doi:10.2147/IDR.S419993.
[6]	JIA Y J, XIONG S, YAO M, et al. HMGB1 inhibition blocks ferroptosis and oxidative stress to ameliorate sepsis-induced acute lung injury by activating the Nrf2 pathway[J]. Kaohsiung J Med Sci, 2024, 40(8):710-721. doi:10.1002/kjm2.12851.
[7]	史阳琳, 杨建雅, 常晴晴, 等. 铁死亡在脓毒症急性肺损伤中的研究进展[J]. 中国比较医学杂志, 2024, 34(6):127-134.
	SHI Y L, YANG J Y, CHANG Q Q, et al. Research progress in the role of ferroptosis in sepsis-associated acute lung injury[J]. Chinese Journal of Comparative Medicine, 2024, 34(6):127-134. doi:10.3969/j.issn.1671-7856.2024.06.017.
[8]	XU Y, BU G. Identification of two novel ferroptosis-associated targets in sepsis-induced cardiac injury:Hmox1 and Slc7a11[J]. Front Cardiovasc Med, 2023, 10:1185924. doi:10.3389/fcvm.2023.1185924.
[9]	LI Q, YU X, YU R, et al. Therapeutic potential of inhibiting hmox1 in sepsis-induced lung injury:a molecular mechanism study[J]. J Biochem Mol Toxicol, 2025, 39(2):e70134. doi:10.1002/jbt.70134.
[10]	ZHANG N, FAN Y, CHEN J, et al. MAPK14 drives ferroptosis and immune dysfunction in pediatric sepsis-induced acute lung injury[J]. Cell Immunol, 2025,411-412:104948. doi:10.1016/j.cellimm.2025.104948.
[11]	SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J]. JAMA, 2016, 315(8):801-810. doi:10.1001/jama.2016.0287.
[12]	RHODES A, EVANS L E, ALHAZZANI W, et al. Surviving sepsis campaign:international guidelines for management of sepsis and septic shock:2016[J]. Intensive Care Med, 2017, 43(3):304-377. doi:10.1007/s00134-017-4683-6.
[13]	LI Z, ZHANG C, LIU Y, et al. Diagnostic and predictive values of ferroptosis-related genes in child sepsis[J]. Front Immunol, 2022, 13:881914. doi:10.3389/fimmu.2022.881914.
[14]	NEU C, BECKERS C, FRANK N, et al. Ribonuclease inhibitor 1 emerges as a potential biomarker and modulates inflammation and iron homeostasis in sepsis[J]. Sci Rep, 2024, 14(1):14972. doi:10.1038/s41598-024-65778-8.
[15]	LIU B, AO S, TAN F, et al. Transcriptomic analysis and laboratory experiments reveal potential critical genes and regulatory mechanisms in sepsis-associated acute kidney injury[J]. Ann Transl Med, 2022, 10(13):737. doi:10.21037/atm-22-845.
[16]	曾琴, 谢榕城, 马杰飞, 等. 基于生物信息学分析铁死亡调控基因与脓毒症诱导肺损伤的关系[J]. 中国呼吸与危重监护杂志, 2024, 23(9):617-624.
	ZENG Q, XIE R C, MA J F, et al. The relationship between ferroptosis regulatory genes and lung injury induced by sepsis based on bioinformatics[J]. Chinese Journal of Respiratory and Critical Care Medicine, 2024, 23(9):617-624. doi:10.7507/1671-6205.202403042.
[17]	SHI R, BAI C, SUN S, et al. Identification of ferroptosis-related key genes associated with immune infiltration in sepsis by bioinformatics analysis and in vivo validation[J]. Gene, 2024, 918:148482. doi:10.1016/j.gene.2024.148482.
[18]	祖一文. 铁死亡相关基因在成人脓毒症中的诊断和预测价值[D]. 唐山: 华北理工大学, 2023:27-29.
	ZU Y W. The diagnostic and predictive value of ferroptosis-related genes in adult sepsis[D]. Tangshan: North China University of Science and Technology, 2023:27-29.
[19]	WU J, CAO X, HUANG L, et al. Construction of a NETosis-related gene signature for predicting the prognostic status of sepsis patients[J]. Heliyon, 2024, 10(17):e36831. doi:10.1016/j.heliyon.2024.e36831.
[20]	LU J, CHEN R, OU Y, et al. Characterization of immune-related genes and immune infiltration features for early diagnosis, prognosis and recognition of immunosuppression in sepsis[J]. Int Immunopharmacol, 2022, 107:108650. doi:10.1016/j.intimp.2022.108650.
[21]	LI Z, YU Y, LIU C, et al. Identification of the key ferroptosis-related genes involved in sepsis progression and experimental validation in vivo[J]. Front Pharmacol, 2022, 13:940261. doi:10.3389/fphar.2022.940261.

组别		n	年龄/岁		男性		BMI/（kg/m²）
未合并组		48	7.9±4.0		23（47.9）		19.3.±3.2
合并ALI组		54	8.3±3.5		29（53.7）		20.1±4.1
t或χ²			0.539		0.341		1.089
组别		PCT/（μg/L）			CRP/（mg/L）		Lac/（mmol/L）		AST/（U/L）
未合并组		1.8±1.2			47.0±23.2		3.5±0.9		34.2±9.5
合并ALI组		2.5±1.5			52.7±24.1		4.2±1.8		35.8±9.7
t		2.581^＊			1.213		8.634^＊＊		0.840
组别	ALT/（U/L）			Tbil/（μmol/L）		SCr/（μmol/L）		BUN/（mmol/L）
未合并组	39.8±11.6			1.13±0.28		87.5±15.9		5.9±1.4
合并ALI组	42.7±12.3			1.14±0.32		92.8±23.9		6.2±1.3
t	1.221			0.167		1.303		1.122

组别		n	年龄/岁		男性		BMI/（kg/m²）
未合并组		48	7.9±4.0		23（47.9）		19.3.±3.2
合并ALI组		54	8.3±3.5		29（53.7）		20.1±4.1
t或χ²			0.539		0.341		1.089
组别		PCT/（μg/L）			CRP/（mg/L）		Lac/（mmol/L）		AST/（U/L）
未合并组		1.8±1.2			47.0±23.2		3.5±0.9		34.2±9.5
合并ALI组		2.5±1.5			52.7±24.1		4.2±1.8		35.8±9.7
t		2.581^＊			1.213		8.634^＊＊		0.840
组别	ALT/（U/L）			Tbil/（μmol/L）		SCr/（μmol/L）		BUN/（mmol/L）
未合并组	39.8±11.6			1.13±0.28		87.5±15.9		5.9±1.4
合并ALI组	42.7±12.3			1.14±0.32		92.8±23.9		6.2±1.3
t	1.221			0.167		1.303		1.122

组别	n	PELOD-2评分	PRISMⅢ评分	SOFA评分
未合并组	48	13.2±4.1	28.0±7.2	7.1±2.5
合并ALI组	54	15.3±5.2	32.9±8.1	10.8±3.1
t		2.245^＊	3.212^＊＊	6.582^＊＊

组别	n	PELOD-2评分	PRISMⅢ评分	SOFA评分
未合并组	48	13.2±4.1	28.0±7.2	7.1±2.5
合并ALI组	54	15.3±5.2	32.9±8.1	10.8±3.1
t		2.245^＊	3.212^＊＊	6.582^＊＊

组别	n	HMOX1/（μg/L）	MAPK14/（μg/L）
未合并组	48	2.71±0.34	3.27±0.43
合并ALI组	54	3.42±0.50	4.04±0.66
t		3.058^＊＊	3.451^＊＊